Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Up 151.6% in December

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 4,000,000 shares, an increase of 151.6% from the November 30th total of 1,590,000 shares. Based on an average daily trading volume, of 93,440,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.1% of the shares of the company are sold short.

Tonix Pharmaceuticals Stock Performance

Shares of NASDAQ:TNXP traded down $0.03 during trading on Friday, reaching $0.34. The company had a trading volume of 73,979,242 shares, compared to its average volume of 30,416,361. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The stock’s fifty day moving average price is $0.22 and its 200 day moving average price is $0.38. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $14.08. The firm has a market capitalization of $63.10 million, a price-to-earnings ratio of -0.01 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. As a group, equities research analysts predict that Tonix Pharmaceuticals will post -17.63 EPS for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Monday, December 23rd. They set a “hold” rating on the stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.